Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines

Cancer Letters

Volumn 227, Issue 2, 2005, Pages 201-212

  Mocanu, Maria Magdalena ^a,b   Fazekas, Zsolt ^a   Petrás, Miklós ^a   Nagy, Péter ^a   Sebestyén, Zsolt ^a   Isola, Jorma ^c   Tímár, József ^d   Park, John W ^e   Vereb, György ^a   Szöllosi, János ^a,f  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF TAMPERE   (Finland)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Confocal microscopy; ErbB; Fluorescence resonance energy transfer; Herceptin resistance; Lipid rafts; Receptor tyrosine kinase; 1 integrin

Indexed keywords

BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURFACE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; LIPID RAFT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; BREAST TUMOR; CELL CULTURE; CELL MEMBRANE; DRUG RESISTANCE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD29; BREAST NEOPLASMS; CELL MEMBRANE; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE MICRODOMAINS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 23844475901     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.028     Document Type: Article

References (40)

1. R. Roskoski Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem. Biophys. Res. Commun. 319 2004 1 11
2. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137
3. S. Paik, and E.T. Liu HER2 as a predictor of therapeutic response in breast cancer Breast Dis. 11 2000 91 102
4. E. Tzahar, H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, and S. Lavi A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol. Cell Biol. 16 1996 5276 5287
5. A.E. Lenferink, R. Pinkas-Kramarski, M.L. van de Poll, M.J. van Vugt, L.N. Klapper, and E. Tzahar Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers Eur. Mol. Biol. Org. J. 17 1998 3385 3397
6. P. Nagy, A. Jenei, S. Damjanovich, T.M. Jovin, and J. Szöllosi Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy Pathol. Oncol. Res. 5 1999 255 271
7. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin. Oncol. 26 1999 60 70
8. A.M. Hommelgaard, M. Lerdrup, and B. van Deurs Association with membrane protrusions makes ErbB2 an internalization-resistant receptor Mol. Biol. Cell 15 2004 1557 1567
9. P. Nagy, G. Vereb, Z. Sebestyén, G. Horváth, S.J. Lockett, and S. Damjanovich Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2 J. Cell Sci. 115 2002 4251 4262
10. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6 2000 443 446
11. A.M. Petit, J. Rak, M.C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R.S. Kerbel Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am. J. Pathol. 151 1997 1523 1530
12. J. Codony-Servat, J. Albanell, J.C. Lopez-Talavera, J. Arribas, and J. Baselga Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells Cancer Res. 59 1999 1196 1201
13. F. Cardoso, M.J. Piccart, V. Durbecq, and A. Di Leo Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin. Breast Cancer 3 2002 247 257
14. A.B. Motoyama, N.E. Hynes, and H.A. Lane The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res. 62 2002 3151 3158
15. Y. Lu, X. Zi, and M. Pollak Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells Int. J. Cancer 108 2004 334 341
16. S.A. Price-Schiavi, S. Jepson, P. Li, M. Arango, P.S. Rudland, L. Yee, and K.L. Carraway Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance Int. J. Cancer 99 2002 783 791
17. P. Nagy, E. Friedländer, M. Tanner, A.I. Kapanen, K.L. Carraway, J. Isola, T.M. Jovin, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line, Cancer Res. 65 (2005) 473-482.
18. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, and A.A. Sahin PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
19. M. Tanner, A.I. Kapanen, T. Junttila, O. Raheem, S. Grenman, J. Elo, K. Elenius, J. Isola, Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer, Mol. Cancer Ther.3 (2004) 1585-1592.
20. G. Vereb, P. Nagy, J.W. Park, and J. Szöllosi Signaling revealed by mapping molecular interactions: implications for ErbB-targeted cancer immunotherapies Clin. Appl. Immunol. Rev. 2 2002 169 186
21. P. Nagy, A. Jenei, A.K. Kirsch, J. Szöllosi, S. Damjanovich, and T.M. Jovin Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy J. Cell Sci. 112 1999 1733 1741
22. S. Munro Lipid rafts: elusive or illusive? Cell 115 2003 377 388
23. L.D. Zajchowski, and S.M. Robbins Lipid rafts and little caves. Compartmentalized signalling in membrane microdomains Eur. J. Biochem. 269 2002 737 752
24. M. Edidin Shrinking patches and slippery rafts: scales of domains in the plasma membrane Trends Cell Biol. 11 2001 492 496
25. T. Harder, P. Scheiffele, P. Verkade, and K. Simons Lipid domain structure of the plasma membrane revealed by patching of membrane components J. Cell Biol. 141 1998 929 942
26. F.G. Giancotti, and E. Ruoslahti Integrin signaling Science 285 1999 1028 1032
27. S. Miyamoto, H. Teramoto, J.S. Gutkind, and K.M. Yamada Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors J. Cell Biol. 135 1996 1633 1642
28. F. Wang, V.M. Weaver, O.W. Petersen, C.A. Larabell, S. Dedhar, and P. Briand Reciprocal interactions between β1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology Proc. Natl Acad. Sci. USA 95 1998 14821 14826
29. B. Leitinger, and N. Hogg The involvement of lipid rafts in the regulation of integrin function J. Cell Sci. 115 2002 963 972
30. R. Falcioni, A. Antonini, P. Nistico, S. Di Stefano, M. Crescenzi, P.G. Natali, and A. Sacchi α6β4 and α6β1 integrins associate with ErbB-2 in human carcinoma cell lines Exp. Cell Res. 236 1997 76 85
31. M.A. Adelsman, J.B. McCarthy, and Y. Shimizu Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase Mol. Biol. Cell 10 1999 2861 2878
32. L. Trón, J. Szöllosi, S. Damjanovich, S.H. Helliwell, D.J. Arndt-Jovin, and T.M. Jovin Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis Biophys. J. 45 1984 939 946
33. Z. Sebestyén, P. Nagy, G. Horváth, G. Vámosi, R. Debets, and J.W. Gratama Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer Cytometry 48 2002 124 135
34. G. Szentesi, G. Horváth, I. Bori, G. Vámosi, J. Szöllosi, and R. Gáspár Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis Comput. Methods Prog. Biomed. 75 2004 201 211
35. G. Vereb, J. Matkó, G. Vámosi, S.M. Ibrahim, E. Magyar, and S. Varga Cholesterol-dependent clustering of IL-2Ra and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts Proc. Natl Acad. Sci. USA 97 2000 6013 6018
36. P. Nagy, L. Bene, M. Balázs, W.C. Hyun, S.J. Lockett, and N.Y. Chiang EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements Cytometry 32 1998 120 131
37. A.M. Gronowski, and P.J. Bertics Modulation of epidermal growth factor receptor interaction with the detergent-insoluble cytoskeleton and its effects on receptor tyrosine kinase activity Endocrinology 136 1995 2198 2205
38. L. Moro, M. Venturino, C. Bozzo, L. Silengo, F. Altruda, and L. Beguinot Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival Eur. Mol. Biol. Org. J. 17 1998 6622 6632
39. H.L. Goel, M. Fornaro, L. Moro, N. Teider, J.S. Rhim, M. King, and L.R. Languino Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by β1 integrins J. Cell Biol. 166 2004 407 418
40. J.A. Engelman, R.J. Lee, A. Karnezis, D.J. Bearss, M. Webster, and P. Siegel Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer J. Biol. Chem. 273 1998 20448 20455